Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Irampanel






●Српски / srpski
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  



In other projects  


●Wikimedia Commons
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Irampanel
Clinical data
ATC code
  • None
Identifiers

  • N,N-Dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine

CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H19N3O2
Molar mass309.369 g·mol−1
3D model (JSmol)

  • CN(C)CCOc1ccccc1c2nc(no2)c3ccccc3

  • InChI=1S/C18H19N3O2/c1-21(2)12-13-22-16-11-7-6-10-15(16)18-19-17(20-23-18)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3

  • Key:QZULPCPLWGCGSL-UHFFFAOYSA-N

Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker.[1][2] It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication.[3][4] Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned,[1] and the drug was ultimately never marketed.

References[edit]

  1. ^ a b Feigin V (June 2002). "Irampanel Boehringer Ingelheim". Current Opinion in Investigational Drugs. 3 (6): 908–910. PMID 12137411.
  • ^ Wang KK, Larner SF, Robinson G, Hayes RL (December 2006). "Neuroprotection targets after traumatic brain injury". Current Opinion in Neurology. 19 (6): 514–519. doi:10.1097/WCO.0b013e3280102b10. PMID 17102687. S2CID 28119069.
  • ^ Sharma SS, Kaundal RK (1 January 2007). "Targeting Molecular Pathways in Stroke". In Ray A, Gulati K (eds.). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7.
  • ^ Weiser T (April 2005). "AMPA receptor antagonists for the treatment of stroke". Current Drug Targets. CNS and Neurological Disorders. 4 (2): 153–159. doi:10.2174/1568007053544129. PMID 15857300.
    • Stub icon

    This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Irampanel&oldid=1192101018"
    Categories: 
    ●Drugs not assigned an ATC code
     ●AMPA receptor antagonists
     ●Anticonvulsants
     ●Dimethylamino compounds
     ●Neuroprotective agents
     ●Oxadiazoles
     ●Sodium channel blockers
     ●Abandoned drugs
     ●Anticonvulsant stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugs with no legal status
     ●Articles containing unverified chemical infoboxes
     ●All stub articles
      


    ●This page was last edited on 27 December 2023, at 16:06 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki